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Abstract 
Background:  
The majority of published scientific papers concerning the role of biochemical markers of first trimester such as 
PAPP-A and free-ß-hCG in predicting future pregnancy complications enhance the importance of these 
parameters.  
Objective:  
To evaluate the role of biochemical markers parameters in other pregnancy disorders after first trimester such as 
Fetal Growth Restriction, Preeclampsia, Preterm Birth, Stillbirth, Fetal Macrosomia.   
Materials and methods: 
As a part of a prospective study, we did study 866 patients that were followed from the beginning of pregnancy 
to delivery, after giving their agreement. Quantity and quality research methods were used and data was 
analyzed by IBM SPSS Statistics. 
Results: 
Our data of showed that 11.4% of this cohort presented one of the above respective pathologies. The risk was 
better related to MoM PAPP-A than free-ß-hCG. Patients with MoM PAPP-A less than cut off 0.5, has double 
risk of having the pathology comparing to those patients with 
Conclusions: 
Consequently, the value of counseling the patient so early, with the information taken from evidence based 
medicine, has importance for them, in order to be more careful after having the results, and make regular control 
with their physician.  
Keywords: Biochemical markers, pregnancy complications, Down syndrome.  
 
Introduction 
A number of proteins in the maternal circulation have been found during the time of pregnancy.  Many of these 
are made or modified by the placenta.  Differences in levels of some of the proteins have been observed in 
patients carrying a fetus with Down syndrome and certain other chromosome abnormalities.  The discovery of 
these slight differences in protein levels has been largely based on observation- we really don't know why they 
work in most cases.  Nevertheless, we can take advantage of these differences in screening protocols.  These are 
referred to as biochemical markers.  Certain patterns of biochemical markers have been associated with fetal 
Down syndrome as well as other conditions.
1,2 
 It is important to know that these proteins change during 
pregnancy, so interpretation requires an knowledge of the gestational age.  Also, the effectiveness of these 
proteins varies with gestational ages.  For example, differences in protein levels may be observed during the 
second trimester but not the first, while other proteins show differences during the first trimester but not the 
second.  
The aim of this study is to evaluate the role of biochemical markers parameters in other pregnancy 
disorders after first trimester such as Fetal Growth Restriction, Preeclampsia, Preterm Birth, Stillbirth, Fetal-
Macrosomia and other.   
 
Materials and methods: 
As a part of a prospective study, we did study 866 patients that were followed from the beginning of pregnancy 
to delivery, after giving their agreement. Quantity and quality research methods were used and data was 
analyzed by IBM SPSS Statistics 2015. 
 
Results and discussion 
Our prospective study of total population 866 patients resulted that 11.4% presented one of the above respective 
pathologies namely Fetal Growth Restriction, Preeclampsia, Preterm Birth, Stillbirth and Fetal-Macrosomia. 
Illustrated in chart 1. 
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Chart 1. Pregnancy disorder other than Down syndrome diagnosed by biochemical markers 
Biochemical markers are used to assess maternal, placental and fetal health. They help to diagnose and 
monitor maternal conditions to name a few, IUGR, preterm labour, gestational diabetes and gestational 
hypertension, pre-eclampsia, trophoblastic disease and fetal chromosomal abnormalities such as Down's 
syndrome. These biochemical and hormonal tests constitute only one aspect of obstetric care. They should be 
used together with clinical findings and imaging, particularly ultrasonography. 
The prevalence of gestational diabetes mellitus ranges from 1 to 14% depending on the populations 
studied.
1, 2 
 Screening for gestational diabetes mellitus is strongly advocated at 26-28 weeks of gestation. This 
enables early intervention which results in significant improvements in both fetal and maternal outcomes.
  
Pre-eclampsia occurs typically in the third trimester and affects 4-8% of pregnancies.
4
 It constitutes a 
triad of pregnancy-associated hypertension, that is, there is no pre-existing hypertension, marked proteinuria -
greater than 300 mg daily and pathological edema. It is thus critical that urinary dipstick testing for protein, 
which can be fully quantitated if required, is performed at each antenatal visit together with blood pressure 
measurement and careful examination for edema. Other findings include rises in serum uric acid, which can 
antedate the onset of hypertension, urea and creatinine. Low haemoglobin and platelet concentrations are 
informative if the patient is suspected to have the severe form of pre-eclampsia - haemolysis-elevated liver 
enzymes-low platelets - HELLP. In the absence of pre-existing pathology, these biochemical parameters should 
return to normal after delivery. 
Down's syndrome is one of the common causes of fetal growth retardation. It is the result of either 
partial or total trisomy of chromosome 21 and is a major obstetric concern, particularly in older women.
1, 2 
 
Important biochemical markers include alpha fetoprotein, HCG, unconjugated oestriol, pregnancy-associated 
plasma protein-A, serum inhibin-A and free β-HCG. These markers are used in various combinations and 
together with ultrasound to increase the detection rate of Down's syndrome. It cannot be over emphasised that 
the gestational age must be correct in order for screening parameters to be accurate. 
Between 11 and 13 weeks, serum pregnancy-associated plasma protein-A, free β-HCG and ultrasound 
assessment of nuchal thickness are most commonly used in the assessment of Down's syndrome.
5
 Due to the 
changing concentrations of these markers in the normal pregnant population, the results are mathematically 
corrected for easy comparison. The nuchal thickness is increased in Down's syndrome and approximately 70% of 
cases will be detected by ultrasound in experienced centres.
1,2 
 In combination with biochemical markers, the 
detection rate increases to 85-90%.
1,2 
 Abnormal results can be followed up with direct karyotyping using 
chorionic villous sampling, but this carries a 0.5-1.0% risk of pregnancy loss in the first trimester.
1,2 
In the second trimester, screening for Down's syndrome traditionally employs the triple test of maternal 
serum HCG, serum unconjugated oestriol and alpha fetoprotein at 15-18 weeks of gestation. Some laboratories 
also measure serum pregnancy-associated plasma protein-A. The combination of these markers and maternal age 
delivers a 60-65% detection rate, but this includes the 5% of women who have a false positive result.
1, 2
 
Transnuchal thickness in the mid to late second trimester does not correlate well with Down's syndrome and 
does not add to the value of biochemical markers.
1,2
  
The results of Down's syndrome screening in the first and second trimester are expressed as the 
proportion of affected pregnancies is accomplished using a risk-assessment program that incorporates nuchal 
thickness (only in the first trimester), biochemistry results and maternal age.
5 
 
Conclusion 
Down syndrome biochemical markers levels are altered in those patients who subsequently developed 
preeclampsia, Fetal Growth Restriction, Preterm Birth, Stillbirth and Fetal-Macrosomia and may be a useful 
screening test for such disorders during pregnancy. 
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